CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis

Leukemia. 2015 May;29(5):1209-10. doi: 10.1038/leu.2014.343. Epub 2014 Dec 8.
No abstract available

Publication types

  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Calreticulin / genetics*
  • DNA Mutational Analysis
  • Europe
  • Follow-Up Studies
  • Humans
  • Incidence
  • Janus Kinase 2 / genetics
  • Mutation*
  • Primary Myelofibrosis / complications
  • Primary Myelofibrosis / diagnosis
  • Primary Myelofibrosis / genetics*
  • Receptors, Thrombopoietin / genetics*
  • Risk Factors
  • Thrombocythemia, Essential / genetics
  • Thrombosis / complications
  • Thrombosis / genetics
  • Treatment Outcome

Substances

  • Calreticulin
  • Receptors, Thrombopoietin
  • MPL protein, human
  • JAK2 protein, human
  • Janus Kinase 2